No abstract

Objective: The INEOX-Plus study aims to compare the efficacy and safety of Deg-U100 and Gla-U300 in people with T1d incorporated to the Flash Glucose Monitoring (FGM) technology for over 6 months. Materials and Methods: Cross-sectional study in 161 of the 260 T1D participants of the INEOX randomized study (NCT 03328845) who were initially randomized between 2017 and 2019 to receive Gla-U300 or Deg-U100 insulin and incorporated to FGM technology after. Participants were re-evaluated in the INEOX_Plus visit, at an average 2.8 years after the final INEOX visit. Sociodemographic variables, insulin dose, plasma HbA1c and episodes of severe hypoglycemia and ketosis in the previous year were collected together with data on Freestyle libre 2® system downloaded from the last 90 days: sensor use, number of daily scans, GMI, mean glucose, CV, TIR 70-180, TBR 69-54, TBR <54, TAR 181-250, TAR >250 and hypoglycemia events- number/90 days and rate/year-. Results: 90 men (56%) and 71 women (44%), mean age 44±11 years, with diabetes evolution of 23.5±10 years belonging to the INEOX study accepted to participate; 75 subjects (46%) used Gla-U300 and 86 (54%) Deg-U100. A significant reduction in HbA1c was observed between the final INEOX and INEOX-Plus visit (7.65±1.04% vs 7.43±0.84%, p= 0.002) regardless of the type and dose of second-generation long-acting insulin analogue used. There were no episodes of severe hypoglycemia or ketoacidosis reported. We did not find significant differences in insulin doses, HbA1c and FGM metrics except in the Hypoglycemia events incidence rate -213.65 vs 260.05 events/person/year; p=0.001 - for Gla-U300 vs Deg-U100 respectively. Conclusions: For people with T1D in routine clinical follow-up with FGM, Gla-U300 and Deg-U100 insulin have a similar effect on the efficacy and safety variables except for significantly lower incidence rate of yearly hypoglycemia events for Gla-U300 users. Disclosure M.S.Ruiz de adana: None. L.I.Navas vela: None. C.Maldonado-araque: None. G.Olveira: Other Relationship; Abbott Diabetes, Novo Nordisk, Speaker's Bureau; Lilly. G.Rojo martínez: None. M.E.Domínguez-lópez: None. M.Vallejo mora: None. N.Colomo: None. F.Linares: None. V.Morillas: Other Relationship; Boehringer Ingelheim and Eli Lilly Alliance. M.Vallejo herrera: None. S.Alonso gallardo: None. M.Padilla fuentes: None. Funding Instituto de Salud Carlos III (PI 17/00861)

Objective: To assess the natural evolution of low-grade squamous intraepithelial lesions (LSIL) in a retrospective study conducted in a specialized primary care setting of patients detected from the cervical cancer prevention program. Materials and Methods: A review of all cytological examinations between January and December 2002, with 24 months follow-up was conducted in LSIL patients. Follow-up with cytological testing and colposcopy were performed every 6 months, and a biopsy was performed in cases that were indicated by protocol. Patients were not systemically or topically treated in any case. Results: During the study period, 4,152 women received cytology testing, and 122 had LSIL (prevalence, 2.9%). One hundred eleven patients (91%) completed the follow-up, and the remaining patients were lost for various reasons. The age distribution was as follows: 3.2% (G20 years), 34.4% (20Y29 years), 25.4% (30Y39 years), 27.2% (40Y49 years), 9% (50Y59 years), and 0.8% (960 years). Spontaneous regression was observed in 79 (71.3%) of women who completed follow-up. Regression was observed in 51.8% of patients within 12Y18 months and in 48.2% of patients within 18Y24 months of cytological testing. Regression according to age group was as follows: 100% (G20 years), 79.5% (20Y29 years), 60.6% (30Y39 years), 81.8% (40Y49 years), 90.9% (50Y59 years), and 100% (960 years). Conclusions: The general tendency of natural regression in LSIL patients without any specific risk factors identified is supported by our results. 2007, American Society for Colposcopy and Cervical Pathology